What is donanemab? A Guide to the New Alzheimer's Drug
•
3 min read
In July 2024, the FDA granted traditional approval for **donanemab** (marketed as Kisunla™), a monoclonal antibody that targets and helps clear amyloid plaques in patients with early symptomatic Alzheimer's disease. This represents a significant advancement in treating the underlying pathology of the disease rather than just managing symptoms.
